Increased FAK activity has already been reported in various cancer cell lines, with demonstrated antitumoral effects of FAK TKI in cancer cells where FAK was activated [27,30,40,60,61,62,63], including NSCLC and SCLC [24,25,26,39]. The gene discussed is PTK2; the disease is non-small cell lung carcinoma.